Use of GnRH depot analogue in the treatment of uterine fibroids

G. Auber, G. Ricci, F. Barciulli, R. Pregazzi, R. Levi d'Ancona, F. G. Toffoletti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Twelve patients with symptomatic uterine fibroid were treated with Goserelin acetate, a depot GnRH analogue administered s.c. in a dosage of 3.6 mg every 28 days for a 6 month period. Mean age of the patients was 39 (26-47). A menopausal-like state, evidenced by hot flushes, depression, vaginal dryness, hysteroscopic endometrial atrophy, and hormonal values (FSH, LH, E2), was seen in all patients. After only two months of treatment, a significant reduction was noted in the size of the fibroid, being even greater than that in the following four months. Only one patient in the series underwent surgery. General tolerability of the drug was optimal. These data suggest the efficiency of this type of treatment in obtaining a significant reduction of fibroid volume as well as subjective symptomatology. The cost-benefit ratio is optimal, allowing postponement of surgery and the possibility of vaginal, as opposed to abdominal, hysterectomy and affronting problems of anaesthesiology and post-operative recovery for patients 'at risk'.

Original languageEnglish
Pages (from-to)185-189
Number of pages5
JournalActa Europaea Fertilitatis
Volume21
Issue number4
Publication statusPublished - 1990

Fingerprint

Leiomyoma
Gonadotropin-Releasing Hormone
Goserelin
Therapeutics
Anesthesiology
Hysterectomy
Atrophy
Cost-Benefit Analysis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Auber, G., Ricci, G., Barciulli, F., Pregazzi, R., Levi d'Ancona, R., & Toffoletti, F. G. (1990). Use of GnRH depot analogue in the treatment of uterine fibroids. Acta Europaea Fertilitatis, 21(4), 185-189.

Use of GnRH depot analogue in the treatment of uterine fibroids. / Auber, G.; Ricci, G.; Barciulli, F.; Pregazzi, R.; Levi d'Ancona, R.; Toffoletti, F. G.

In: Acta Europaea Fertilitatis, Vol. 21, No. 4, 1990, p. 185-189.

Research output: Contribution to journalArticle

Auber, G, Ricci, G, Barciulli, F, Pregazzi, R, Levi d'Ancona, R & Toffoletti, FG 1990, 'Use of GnRH depot analogue in the treatment of uterine fibroids', Acta Europaea Fertilitatis, vol. 21, no. 4, pp. 185-189.
Auber G, Ricci G, Barciulli F, Pregazzi R, Levi d'Ancona R, Toffoletti FG. Use of GnRH depot analogue in the treatment of uterine fibroids. Acta Europaea Fertilitatis. 1990;21(4):185-189.
Auber, G. ; Ricci, G. ; Barciulli, F. ; Pregazzi, R. ; Levi d'Ancona, R. ; Toffoletti, F. G. / Use of GnRH depot analogue in the treatment of uterine fibroids. In: Acta Europaea Fertilitatis. 1990 ; Vol. 21, No. 4. pp. 185-189.
@article{5bf1020960514bbb8d21be5334b5abb0,
title = "Use of GnRH depot analogue in the treatment of uterine fibroids",
abstract = "Twelve patients with symptomatic uterine fibroid were treated with Goserelin acetate, a depot GnRH analogue administered s.c. in a dosage of 3.6 mg every 28 days for a 6 month period. Mean age of the patients was 39 (26-47). A menopausal-like state, evidenced by hot flushes, depression, vaginal dryness, hysteroscopic endometrial atrophy, and hormonal values (FSH, LH, E2), was seen in all patients. After only two months of treatment, a significant reduction was noted in the size of the fibroid, being even greater than that in the following four months. Only one patient in the series underwent surgery. General tolerability of the drug was optimal. These data suggest the efficiency of this type of treatment in obtaining a significant reduction of fibroid volume as well as subjective symptomatology. The cost-benefit ratio is optimal, allowing postponement of surgery and the possibility of vaginal, as opposed to abdominal, hysterectomy and affronting problems of anaesthesiology and post-operative recovery for patients 'at risk'.",
author = "G. Auber and G. Ricci and F. Barciulli and R. Pregazzi and {Levi d'Ancona}, R. and Toffoletti, {F. G.}",
year = "1990",
language = "English",
volume = "21",
pages = "185--189",
journal = "Acta Europaea Fertilitatis",
issn = "0587-2421",
number = "4",

}

TY - JOUR

T1 - Use of GnRH depot analogue in the treatment of uterine fibroids

AU - Auber, G.

AU - Ricci, G.

AU - Barciulli, F.

AU - Pregazzi, R.

AU - Levi d'Ancona, R.

AU - Toffoletti, F. G.

PY - 1990

Y1 - 1990

N2 - Twelve patients with symptomatic uterine fibroid were treated with Goserelin acetate, a depot GnRH analogue administered s.c. in a dosage of 3.6 mg every 28 days for a 6 month period. Mean age of the patients was 39 (26-47). A menopausal-like state, evidenced by hot flushes, depression, vaginal dryness, hysteroscopic endometrial atrophy, and hormonal values (FSH, LH, E2), was seen in all patients. After only two months of treatment, a significant reduction was noted in the size of the fibroid, being even greater than that in the following four months. Only one patient in the series underwent surgery. General tolerability of the drug was optimal. These data suggest the efficiency of this type of treatment in obtaining a significant reduction of fibroid volume as well as subjective symptomatology. The cost-benefit ratio is optimal, allowing postponement of surgery and the possibility of vaginal, as opposed to abdominal, hysterectomy and affronting problems of anaesthesiology and post-operative recovery for patients 'at risk'.

AB - Twelve patients with symptomatic uterine fibroid were treated with Goserelin acetate, a depot GnRH analogue administered s.c. in a dosage of 3.6 mg every 28 days for a 6 month period. Mean age of the patients was 39 (26-47). A menopausal-like state, evidenced by hot flushes, depression, vaginal dryness, hysteroscopic endometrial atrophy, and hormonal values (FSH, LH, E2), was seen in all patients. After only two months of treatment, a significant reduction was noted in the size of the fibroid, being even greater than that in the following four months. Only one patient in the series underwent surgery. General tolerability of the drug was optimal. These data suggest the efficiency of this type of treatment in obtaining a significant reduction of fibroid volume as well as subjective symptomatology. The cost-benefit ratio is optimal, allowing postponement of surgery and the possibility of vaginal, as opposed to abdominal, hysterectomy and affronting problems of anaesthesiology and post-operative recovery for patients 'at risk'.

UR - http://www.scopus.com/inward/record.url?scp=0025649955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025649955&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 185

EP - 189

JO - Acta Europaea Fertilitatis

JF - Acta Europaea Fertilitatis

SN - 0587-2421

IS - 4

ER -